Skip to content
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — Maj 2024

Genmab — Maj 2024

Planlagt Fastgjort Låst Flyttet Genmab
540 Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • P Offline
    P Offline
    ProinvestorNEWS
    wrote on sidst redigeret af
    #140

    Det drejer sig om en behandling bestående af Darzalex, og kræftmidlerne Revlimid og Velcade samt hormonpræparatet Dexamethason, skriver Bloomberg Intelligence.

    Undersøgelsen viser ifølge Bloomberg Intelligence, at behandlingen allerede nu bruges i tæt på 40 pct. af patienterne i USA og EU som førstebehandling.

    1 Reply Last reply
    0
    • P Offline
      P Offline
      ProinvestorNEWS
      wrote on sidst redigeret af
      #141

      Darzalex er i forvejen en stor sællert for Genmab og partneren Johnson & Johnson.

      I år venter Genmab, at Johnson & Johnsons salg af Darzalex løber op i 10,9-11,5 mia. dollar, og Genmab venter uændret en royaltyindtægt fra Darzalex-salget på 12,6-13,3 mia. kr.

      .\˙ MarketWire

      1 Reply Last reply
      0
      • B Offline
        B Offline
        bibob
        wrote on sidst redigeret af
        #142

        God morgen. 🙂

        1 Reply Last reply
        0
        • E Offline
          E Offline
          E_L
          wrote on sidst redigeret af
          #143

          A New Drug Is Helping Cervical Cancer Patients Live Longer https://www.verywellhealth.com/tivdak-outcomes-for-cervical-cancer-patients-8643474

          1 Reply Last reply
          0
          • P Offline
            P Offline
            peter12
            wrote on sidst redigeret af
            #144

            Interview med Thai https://clinicaledge.xtalks.com/magazine/issue2/breakthroughs-in-antibody-therapeutics

            1 Reply Last reply
            0
            • E Offline
              E Offline
              E_L
              wrote on sidst redigeret af
              #145

              Genmab's Silver Anniversary: Reflecting on 25 Years of Breakthroughs in Antibody Therapeutics

              Interviewee: Tahi Ahmadi https://clinicaledge.xtalks.com/magazine/issue2/breakthroughs-in-antibody-therapeutics

              1 Reply Last reply
              0
              • E Offline
                E Offline
                E_L
                wrote on sidst redigeret af
                #146

                peter already posted that i see. another
                coffee 😉

                1 Reply Last reply
                0
                • P Offline
                  P Offline
                  peter12
                  wrote on sidst redigeret af
                  #147

                  It was the short version with typos 😉

                  1 Reply Last reply
                  0
                  • T Offline
                    T Offline
                    transalp
                    wrote on sidst redigeret af
                    #148

                    Go morgen... 🙂

                    1 Reply Last reply
                    0
                    • E Offline
                      E Offline
                      E_L
                      wrote on sidst redigeret af
                      #149

                      In "Super-Aging" Japan, the Life Sciences Market is Booming https://www.jetro.go.jp/en/invest/insights/japan-insight/lifesciences-market-booming.html

                      1 Reply Last reply
                      0
                      • R Offline
                        R Offline
                        Riis7
                        wrote on sidst redigeret af
                        #150

                        You nede to be
                        super aging to see Genmab in new ATH;-)

                        1 Reply Last reply
                        0
                        • R Offline
                          R Offline
                          Riis7
                          wrote on sidst redigeret af
                          #151

                          need

                          1 Reply Last reply
                          0
                          • StockBullS Offline
                            StockBullS Offline
                            StockBull
                            wrote on sidst redigeret af
                            #152

                            skør kurs p.t. Burde ligge over 3500 hvis JNJ opter-ind

                            1 Reply Last reply
                            0
                            • StockBullS Offline
                              StockBullS Offline
                              StockBull
                              wrote on sidst redigeret af
                              #153

                              så nemme penge for den spekulative investor som er villig til at tage en risiko på ca. 35% for at JNJ ikke opter-ind. 65% mulighed for at score 1500 kurspoint og 35% risiko for at tabe vel max 500 kurspoint.

                              1 Reply Last reply
                              0
                              • E Offline
                                E Offline
                                E_L
                                wrote on sidst redigeret af
                                #154

                                Teprotumumab Treats Thyroid Eye Disease Across Age https://www.medscape.com/viewarticle/teprotumumab-treats-thyroid-eye-disease-across-age-2024a1000906?form=fpf

                                1 Reply Last reply
                                0
                                • R Offline
                                  R Offline
                                  Raun
                                  wrote on sidst redigeret af
                                  #155

                                  @Riis7 .... Som jeg forstår det, har du ikke aktier i Genmab mere..... Vil du ikke være sød at lade være med at være en del af debatten, så længe du kun kommer med intetsigende kommentarer?

                                  1 Reply Last reply
                                  0
                                  • G Offline
                                    G Offline
                                    Goose3
                                    wrote on sidst redigeret af
                                    #156

                                    Novo viser gode resultater
                                    med mim8. Burde der ikke komme noget fra Genmab om det

                                    1 Reply Last reply
                                    0
                                    • R Offline
                                      R Offline
                                      Riis7
                                      wrote on sidst redigeret af
                                      #157

                                      Jeg har lidt i pension og tænker alle må skrive om de har aktier eller ej

                                      1 Reply Last reply
                                      0
                                      • P Offline
                                        P Offline
                                        ProinvestorNEWS
                                        wrote on sidst redigeret af
                                        #158

                                        Novos blødermedikamant Mim8 når et af sine endemål i dag
                                        https://www.proinvestor.com/boards/120390

                                        1 Reply Last reply
                                        0
                                        • SolsenS Offline
                                          SolsenS Offline
                                          Solsen
                                          wrote on sidst redigeret af
                                          #159

                                          Udsigt til yderligere milestones og royalty 🙂

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper